Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Barbara WillekensSilvia Presas-RodríguezM J MansillaJudith DerdelinckxWai-Ping LeeGriet NijsMaxime De LaereInez WensPatrick CrasPaul ParizelWim Van HeckeAnnemie RibbensThibo BillietGeert AdamsMarie-Madeleine CouttenyeJuan Navarro-BarriusoAina Teniente-SerraBibiana Quirant-SánchezAscensión Lopez-Diaz de CerioSusana InogésFelipe ProsperAnke KipHerman VerheijCatharina C GrossHeinz WiendlMarieke Sm Van HamAnja Ten BrinkeAna Maria BarriocanalAnna Massuet-VilamajóNiel HensZwi BernemanEva Martínez-CáceresNathalie CoolsCristina Ramo-Tellonull null

Published in: BMJ open (2019)

NCT02618902 and NCT02903537; EudraCT numbers: 2015-002975-16 and 2015-003541-26.

Keyphrases

dendritic cells
multiple sclerosis
clinical trial
regulatory t cells
immune response
single cell
mass spectrometry
white matter
randomized controlled trial
stem cells
phase ii
open label
replacement therapy
study protocol